Aravive Inc.
| NASDAQ: ARAV | Healthcare / Biotechnology / USA |
| 0.1387 | -0.0049 | -3.41% | Vol 1.20M | 1Y Perf -84.31% |
| Sep 22nd, 2023 16:00 DELAYED |
| BID | 0.1386 | ASK | 0.1410 | ||
| Open | 0.1404 | Previous Close | 0.1436 | ||
| Pre-Market | - | After-Market | 0.14 | ||
| - - | 0.00 2.24% |
| Target Price | 9.40 | Analyst Rating | Hold 3.00 | |
| Potential % | 6.68K | Finscreener Ranking | ★★ 46.50 | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | + 35.26 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★★ 52.91 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 1.20 | Earnings Rating | Strong Buy | |
| Market Cap | 10.20M | Earnings Date | 9th Nov 2023 | |
| Alpha | -0.04 | Standard Deviation | 0.30 | |
| Beta | 2.40 |
Today's Price Range 0.13850.1434 | 52W Range 0.11042.46 | 5 Year PE Ratio Range -2.10-1.10 |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -13.31% | ||
| 1 Month | -11.03% | ||
| 3 Months | -90.50% | ||
| 6 Months | -93.89% | ||
| 1 Year | -84.31% | ||
| 3 Years | -97.29% | ||
| 5 Years | -98.35% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -24.66 | |||
ROE last 12 Months | -196.99 | |||
ROA (5Y Avg) | -21.82 | |||
ROA last 12 Months | -112.15 | |||
ROC (5Y Avg) | -52.26 | |||
ROC last 12 Months | -149.10 | |||
Return on invested Capital Q | -57.53 | |||
Return on invested Capital Y | -23.59 | |||
Assets Turnover | 0.20 | |||
Receivables Turnover | 2.50 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.70 | ||||
| 6.64 | ||||
| 12.49 | ||||
| - | ||||
| -2.00 | ||||
| -2.29 | ||||
| 6.64 | ||||
| 0.25 | ||||
| 76.66M | ||||
| Forward PE | -0.55 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.40 | ||||
| 1.60 | ||||
| 0.14 | ||||
| 0.31 | ||||
| - | ||||
| Leverage Ratio | 2.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -747.30 | ||||
| -737.00 | ||||
| -1 603.30 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 7.66M | ||||
| 0.13 | ||||
| 29.60 | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -0.30 | -0.12 | 60.00 |
| Q01 2023 | -0.33 | -0.22 | 33.33 |
| Q04 2022 | -0.33 | -0.46 | -39.39 |
| Q03 2022 | -0.64 | -0.51 | 20.31 |
| Q02 2022 | -0.62 | -0.61 | 1.61 |
| Q01 2022 | -0.53 | -0.62 | -16.98 |
| Q04 2021 | -0.64 | -0.62 | 3.12 |
| Q03 2021 | -0.42 | -0.53 | -26.19 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | -0.23 | 25.81 | Positive |
| 12/2023 QR | -0.21 | 36.36 | Positive |
| 12/2023 FY | -0.61 | 51.59 | Positive |
| 12/2024 FY | -0.29 | 79.86 | Positive |
| Next Report Date | 9th Nov 2023 |
| Estimated EPS Next Report | -0.23 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 1.20M |
| Shares Outstanding | 73.56K |
| Shares Float | 35.74M |
| Trades Count | 2.15K |
| Dollar Volume | 173.50K |
| Avg. Volume | 7.60M |
| Avg. Weekly Volume | 3.17M |
| Avg. Monthly Volume | 12.99M |
| Avg. Quarterly Volume | 6.63M |
Aravive Inc. (NASDAQ: ARAV) stock closed at 0.1387 per share at the end of the most recent trading day (a -3.41% change compared to the prior day closing price) with a volume of 1.20M shares and market capitalization of 10.20M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 17 people. Aravive Inc. CEO is Gail McIntyre.
The one-year performance of Aravive Inc. stock is -84.31%, while year-to-date (YTD) performance is -89.49%. ARAV stock has a five-year performance of -98.35%. Its 52-week range is between 0.1104 and 2.46, which gives ARAV stock a 52-week price range ratio of 1.20%
Aravive Inc. currently has a PE ratio of -0.70, a price-to-book (PB) ratio of 6.64, a price-to-sale (PS) ratio of 12.49, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -112.15%, a ROC of -149.10% and a ROE of -196.99%. The company’s profit margin is -%, its EBITDA margin is -737.00%, and its revenue ttm is $7.66 Million , which makes it $0.13 revenue per share.
Of the last four earnings reports from Aravive Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.23 for the next earnings report. Aravive Inc.’s next earnings report date is 09th Nov 2023.
The consensus rating of Wall Street analysts for Aravive Inc. is Hold (3), with a target price of $9.4, which is +6 677.22% compared to the current price. The earnings rating for Aravive Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aravive Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aravive Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 12.35, ATR14 : 0.03, CCI20 : -21.58, Chaikin Money Flow : -0.08, MACD : -0.09, Money Flow Index : 76.49, ROC : 3.28, RSI : 27.79, STOCH (14,3) : 27.22, STOCH RSI : 0.54, UO : 46.70, Williams %R : -72.78), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aravive Inc. in the last 12-months were:
Aravive Inc.
Aravive Inc is a clinical-stage biotechnology company. It focuses on developing therapies that target important survival pathways for both solid tumors as well as hematologic malignancies. The company's lead candidate AVB-500 is developed as a targeted therapy against ovarian cancer.
CEO: Gail McIntyre
Telephone: +1 936 355-1910
Address: 3730 Kirby Drive, Houston 77010, TX, US
Number of employees: 17
